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The exchange factor Ras-GRF2 activates Ras-dependent and
Rac-dependent mitogen-activated protein kinase pathways
Wing-Tze Fan*, C. Anne Koch†, Carmen L. de Hoog*, Neil P. Fam* 
and Michael F. Moran*
Ras and Rac are membrane-associated GTPases that
function as molecular switches activating intracellular
mitogen-activated protein kinase (MAPK) cascades and
other effector pathways in response to extracellular
signals [1]. Activation of Ras and Rac into their GTP-
bound conformations is directly controlled by specific
guanine-nucleotide exchange factors (GEFs), which
catalyze GDP release. Several Ras-specific GEFs that are
related to the budding yeast protein Cdc25p have been
described, whereas GEFs for Rac-related GTPases contain
a region that is homologous to the oncoprotein Dbl [2,3].
The Ras-GRF1 and Ras-GRF2 proteins, which couple Ras
activation to serpentine receptors and calcium signals,
contain both Cdc25 and Dbl homology (DH) regions [3,4].
Here, we demonstrate that Ras-GRF2 is a bifunctional
signaling protein that is able to bind and activate Ras and
Rac, and thereby coordinate the activation of the
extracellular-signal-regulated kinase (ERK) and stress-
activated protein kinase (SAPK) pathways.
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Results and discussion
A property common to Cdc25-related and Dbl-related GEF
domains is their relatively high affinity for the nucleotide-
free form of their target GTPase. This likely reflects their
catalytic mechanism of stabilizing an otherwise unfavorable
nucleotide-free intermediate state following initial complex
formation with a GDP-bound GTPase. Ras-GRF2 was able
to bind specifically to nucleotide-free Ras [4]; it also bound
Rac1 and — to a much lesser extent — RhoA, but not
Cdc42 (Figure 1a). The interaction with Ras was a function
of the Cdc25 domain and was not affected by deletion of
the DH domain. Conversely, Rac1 binding required the
DH domain, and remained, albeit at somewhat reduced
levels, in the protein lacking the Cdc25 domain (Figure 1a).
These results suggest that Ras-GRF2 may be a bifunctional
GEF. In agreement with this, immunoprecipitates contain-
ing Ras-GRF2 catalyzed the exchange of bound GDP for
32P-labeled GTP in vitro on both Ras and Rac1, but not on
RhoA or Cdc42 (Figure 1b).
Ras-GRF2, and its close relative Ras-GRF1 (also known
as Cdc25Mm), which is expressed primarily in neurons
[3], binds calmodulin (CaM) and activates Ras in
Figure 1
Ras-GRF2 interactions with Ras and Rho-family GTPases mediated by
the Ras-GRF2 Cdc25 and DH domains. (a) Glutathione-S-transferase
(GST) alone or linked to Ras, RhoA, Rac1 or Cdc42 were prepared in
either their nucleotide-free (NF), GDP-bound (GDP) or GTPγS-bound
(GTPγS) forms and analyzed for their interactions with FLAG-epitope-
tagged Ras-GRF2 (WT, top panels), and mutant versions lacking the
DH domain (∆DH, middle panels) or Cdc25 domain (∆Cdc25, bottom
panels). Incubations were performed in the presence (+) or absence
(–) of cell lysate. (b) Ras GEF and Rac1 GEF activities associated
with Ras-GRF2. Ras-GRF2-catalyzed release of unlabeled GDP and
association of 32P-labeled GTP with GST or the indicated GTPases
during a 30 min incubation period. Values are means ± s.e.m. for four
independent experiments. No GEF activity was detected with GST or
anti-FLAG antibody immunoprecipitates from control 293 cells.
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response to an elevation in intracellular calcium [3,4].
Analysis of activated GTP-bound Ras in cell lysates
expressing Ras-GRF2 indicated that activation of Ras by
Ras-GRF2 requires the Cdc25 domain, but can occur in
the absence of the DH domain (Figure 2a). Consistent
with this, removal of the DH domain from Ras-GRF2
did not diminish its basal or calcium-stimulated activa-
tion of the MAP kinase ERK1 (Figure 2). Deletion of
the Cdc25 domain, or the IQ sequence, which is
required for the CaM interaction [4], impaired ERK1
activation by Ras-GRF2 in response to calcium
ionophore treatment (Figure 2). These results indicate
that the Cdc25 domain, but not the DH domain, 
is involved in Ras-GRF2-mediated activation of Ras 
and ERK.
SAPK (also known as Jun N-terminal kinase or JNK) is a
MAPK distinct from ERK, and is activated downstream
of Rac1 and Cdc42 [1]. Activation of SAPK requires dual
phosphorylation in its kinase domain [1]. In 293T cells
transfected with a control vector, ionomycin treatment
did not cause phosphorylation of SAPK, whereas the
treatment of cells with anisomycin, a potent activator of
the SAPK pathway, caused both p46 and p54 isoforms of
SAPK to become reactive with antibodies specific for
phosphorylated SAPK (Figure 3a). Expression of
Ras-GRF2, even in unstimulated cells, caused p54
SAPK to be phosphorylated to levels comparable to that
seen with anisomycin treatment. Treatment of cells with
ionomycin did not further increase SAPK phosphoryla-
tion, whereas SAPK phosphorylation was further
increased in Ras-GRF2-expressing cells by treatment
with anisomycin (Figure 3a). Measurement of substrate
binding and SAPK activity in vitro indicated that the
expression of Ras-GRF2 caused an elevation in basal
SAPK activity approximately fivefold over that seen 
in unstimulated vector-transfected cells. Calcium
ionophore treatment of cells expressing Ras-GRF2
caused an increase in SAPK activity 14-fold above that
seen in the untreated control cells (Figure 3b). SAPK
activation by Ras-GRF2 was abolished in the ∆IQ
mutant (Figure 3b) suggesting that both the Rac and Ras
GEF activities of Ras-GRF2 are governed by its interac-
tion with CaM. This effect is likely to be indirect as the
∆IQ mutant, or chelator-treated Ras-GRF2 that was not
associated with CaM, displayed wild-type levels of Ras
and Rac GEF activity in vitro (data not shown). The
IQ–CaM interaction may therefore influence the interac-
tion of Ras-GRF2 with its targets, possibly by affecting
Ras-GRF2 subcellular localization.
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(a) Cdc25-domain-dependent Ras activation by Ras-GRF2. The ∆DH
mutant of Ras-GRF2 still caused activation of Ras. Ras–GTP was
recovered from cell lysates by binding to immobilized GST containing
the Ras–GTP-binding domain of Raf [13]. After correction for the
amount of Ras-GRF2 protein expressed (top panel), Ras activation
was determined to be equivalent in cells expressing WT and ∆DH;
Ras was not activated in cells expressing ∆Cdc25 or the vector
control. Constitutively activated Ras-V12 was used as the positive
control (lane 5; a shorter exposure of lane 5 in the middle panel was
spliced into the figure). (b,c) Ras-GRF2-induced calcium-dependent
ERK1 activation requires the Cdc25 domain, but not the DH domain.
(b) Relative ERK1 activation by Ras-GRF2 or the deletion mutants.
Immune-complex kinase assays were performed to assess the ability
of ERK1 to phosphorylate myelin basic protein (MBP) as a measure of
ERK1 activity (bottom panel). The pcDNA3 vector (lanes 1,2), FLAG-
tagged wild-type GRF2 (WT, lanes 3,4) or the GRF2 deletion mutants
∆IQ (lanes 5,6), ∆DH (lanes 7,8) or ∆Cdc25 (lanes 9,10) were co-
transfected with Myc-epitope-tagged ERK1 in 293T cells; 48 h post-
transfection, cells were deprived of serum for 18 h and then treated
with (lanes 2,4,6,8,10) or without (lanes 1,3,5,7,9) 5 µM ionomycin
(Ca2+). Ectopic protein expression was verified by immunoblotting:
Ras-GRF2 (anti-FLAG antibody, top panel); ERK1 (9E10 anti-Myc
antibody, middle panel). Ig, immunoglobulin. (c) Histogram showing
Ras-GRF2-induced ERK1 activity. Results from the above
experiments were quantified using a phosphorimager. MBP
phosphorylation was corrected for the amount of ERK1 in each
sample. The histogram is derived from mean values ± s.e.m. from
three independent experiments.
Ras-GRF2-mediated activation of SAPK is not simply a
consequence of the activation of the Ras pathway, but
rather occurs as a function of the Ras-GRF2 DH domain.
The ∆DH mutant, which behaved like the wild-type
protein with respect to ERK activation (see Figure 2), was
completely ineffective towards SAPK. The ∆Cdc25
protein, which is defective for Ras interaction and activa-
tion, retained some ability to activate the SAPK pathway,
exhibiting a threefold activation of SAPK in unstimulated
cells that was increased to approximately fivefold follow-
ing ionomycin treatment. The diminished activation of
SAPK caused by the deletion of the Cdc25 domain may
reflect a contribution of this domain or of the activated
Ras pathway on the ability of Ras-GRF2 to interact with
Rac in vivo. The ∆Cdc25 protein, like the other variants
described here and the wild-type protein, was found to be
stably expressed in 293 cells, and deletion of the Cdc25
domain did not affect Ras-GRF2-associated in vitro Rac
GEF activity or its domain structure as determined by
partial proteolysis with trypsin (data not shown).
Ras and related GTPases harboring mutations at amino-
acid position 17 (N17), or its equivalent, display impaired
nucleotide interactions, and have been exploited as effec-
tive dominant-negative inhibitors of GEFs [5–7]. Ras-N17
and Rac-N17, when expressed individually, were effective
inhibitors of both ERK and SAPK activation by Ras-GRF2
(Figure 4). These results are consistent with the strong
binding of the Ras-GRF2 Cdc25 and DH domains to
nucleotide-free Ras and Rac, respectively (Figure 1), and
indicate that both the Cdc25 and DH domains are effec-
tively inhibited when either one is engaged with an N17
protein. The ability of either dominant-negative protein to
inhibit signaling by both of the GEF domains suggests that
Ras-GRF2 is indeed the common target of both Ras-N17
and Rac-N17, and that only one of the GEF domains of
Ras-GRF2 may function at a time. By virtue of its two GEF
domains, Ras-GRF2 may be able to activate Ras and Rac in
a coordinated fashion, and this may constitute a form of
cross-talk between Ras and Rac signaling pathways.
Activation of Rac and membrane ruffling can occur down-
stream of Ras and involves phosphatidylinositol (PI) 3-
kinase [8], possibly by activating a Rac GEF activity
associated with the Sos DH domain [9]. Ras-GRF2-medi-
ated activation of SAPK was not inhibited by the PI 3-
kinase inhibitor wortmannin (data not shown) suggesting
that the ability of Ras-GRF2 to activate Rac and the SAPK
pathway does not require activation of PI 3-kinase. Never-
theless, as has been suggested for other cases of wortman-
nin-resistant Rac activation [8], it is possible that a
wortmannin-resistant PI 3-kinase may provide a co-stimula-
tory signal to enable Ras-GRF2-mediated activation of Rac.
Activated (V12) versions of Ras and Rac do not stimulate
SAPK in 293T cells ([10]; data not shown), whereas our
results suggest that 293T cells expressing Ras-GRF2 have
acquired a Rac-to-SAPK pathway. A model to explain this
is that Ras-GRF2 facilitates the interaction of Rac with
effector(s) responsible for the activation of SAPK. Despite
its interactions with Rac and susceptibility to inhibition by
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Figure 3
Ras-GRF2-induced phosphorylation and activation of SAPK.
(a) Transfected 293 cells were treated with 5 µM ionomycin (Ca2+,
lanes 2,5) or 2 µg/ml anisomycin (An, lanes 3,6), or were left untreated
(–, lanes 1,4). Lysates (25 µg protein) were analyzed by
immunoblotting for expression of Ras-GRF2 (anti-FLAG antibody,
upper panel), SAPK (anti-hemagglutinin (HA) antibody, middle panel),
and phosphorylated SAPK (anti-pSAPK antibody, lower panel).
Anisomycin treatment or expression of Ras-GRF2 induced
phosphorylation of SAPK. A more slowly-migrating form of SAPK
(pSAPK), possibly a consequence of its phosphorylation, was
detected in cells expressing Ras-GRF2 (lanes 4–6, middle panel). 
(b) Histogram indicating Ras-GRF2-mediated and Ca2+ (ionomycin
treatment)-induced SAPK activation that was dependent on the IQ and
DH domains and was stimulated by calcium ionophore treatment
(Ca2+). Cells (293T) were co-transfected with plasmids as described
in Figure 2, but the ERK1 construct was substituted by one encoding
HA-tagged SAPK. SAPK was isolated from lysates by association with
GST–c-Jun, and these immobilized complexes were introduced into
kinase reactions containing [γ-32P]ATP. Quantification of SAPK
expression, monitored by immunoblotting and chemiluminescence
detection, and phosphorylation of gel-resolved GST–c-Jun, was
performed using a phosphorimager. Mean values ± s.e.m. from three
independent experiments are shown.
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Rac-N17, however, it remains possible that Ras-GRF2
affects SAPK by a Rac-independent mechanism.
Ras and Rac each interact with a distinct set of effector
proteins and an overlapping set of exchange factors
including, at least, Ras-GRF2 and Sos. Rac-mediated
changes in the actin cytoskeleton, MAPK cascades, and
transcription are important components of the cellular
response to growth factors and other events that concomi-
tantly cause activation of Ras [8,11,12]. Our results suggest
that Ras-GRF2 is a bifunctional protein able to activate
both Ras and Rac and thereby coordinate the signaling by
otherwise distinct MAPK cascades. It remains to be deter-
mined whether Ras-GRF2 affects any of the other Ras
and Rac effector pathways, and whether exchange 
factors in general function as determinants of effector
protein–GTPase interactions.
Supplementary material
Additional methodological details are published with this paper on the
internet.
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Figure 4
Activation of both ERK and SAPK by Ras-GRF2 is inhibited by
dominant-negative forms of Ras and Rac1. (a) Co-expression of either
Ras-N17 or Rac1-N17 with Ras-GRF2 and ERK1 by transient
transfection of 293T cells inhibited basal and calcium-ionophore-
induced ERK1 activity. Ras-GRF2 expression was confirmed by
immunoblotting with anti-FLAG antibody, and ERK1 activity determined
by assessing MBP phosphorylation as described in the legend to
Figure 2. (b) Similarly, Ras-GRF2-mediated activation of SAPK,
measured by immunoblotting with anti-pSAPK antibodies (as
described in Figure 3), was also inhibited by co-expression of Ras-N17
or Rac1-N17 with Ras-GRF2 and HA-tagged SAPK. (c) Immunoblot
analysis confirmed expression of Ras-N17 and Myc-tagged Rac1-N17
proteins. The Cdc25 and DH domains of Ras-GRF2 interact
specifically with Ras and Rac, respectively (see Figure 1). Assuming
that the N17 derivatives retain this specificity for the different GEF
domains of Ras-GRF2, these results indicate that when either one of
the GEF domains is engaged with an inhibitor, the other GEF domain
is unable to function. 
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Materials and methods
Ras-GRF2 interaction with GTPases
Ras-GRF2 codons 245–504 were deleted to make the ∆DH mutant
using polymerase chain reaction (PCR)-based methods as described
previously for ∆IQ [4]. The ∆Cdc25 mutant was made by deletion of
codons 932–1189 as an EcoRV fragment. Ras, RhoA, Rac1 and
Cdc42, prepared as GST fusion proteins (20 µg) [S1,S2] immobilized
on glutathione–agarose beads (approximately 1 mg protein/ml resin),
were rendered free of nucleotide by incubation for 20 min at 23°C in
nucleotide exchange buffer (NEB; 20 mM Tris-HCl pH 7.5, 20 mM
NaCl, 5% glycerol, 1 mM dithiothreitol, 0.1% Triton X-100) supple-
mented with 10 mM EDTA. Nucleotide-bound GTPases were prepared
by incubating nucleotide-free proteins for 25 min at 23°C in NEB con-
taining 10 mM MgCl2 plus 200 µM GTP or 20 µM GTPγS. The
GTPases were resuspended in 500 µl of the same supplemented NEB
buffer used in their preparation, then combined with an equal volume
(approximately 1 mg protein) of cell lysate. Clarified lysates were pre-
pared from 293T cells transfected with pcDNA3, or
pcDNA3–FLAG–Ras-GRF2, or derivatives containing the ∆DH or
∆Cdc25 mutations [4], in 20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1%
Triton X-100, 0.1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride
(AEBSF) and 10 µg aprotinin/ml. Following incubation for 3 h at 4°C,
beads were washed extensively with their respective nucleotide deplet-
ing/binding buffer, and then bound Ras-GRF2 was measured by
immunoblotting with the M2 anti-FLAG antibody (Kodak) and chemilu-
minescence imaging [4].
Ras and Rac exchange factor assays
Cells (293) expressing Ras-GRF2 were rinsed once with ice-cold PBS
and lysed with 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 1% Nonidet P-40,
50 mM NaF, 10 mM NaPPi, 1 mM Na-orthovanadate, 10 µg
aprotinin/ml, 0.1 mM AEBSF and 10 µg leupeptin/ml. Lysates (107 cell
equivalents) were clarified and incubated with an affinity gel containing
5 µg anti-FLAG antibody for 90 min at 4°C. Immunoprecipitates were
washed twice with lysis buffer and twice with exchange buffer (25 mM
Tris-HCl pH 7.5, 50 mM NaCl, 0.06% Nonidet P-40, 1 mM MgCl2,
1 mM dithiothreitol, 1.25 mg bovine serum albumin/ml). Exchange
assays (20 µl per reaction) were performed essentially as described in
Downward [S3] and contained GTPase (100 ng, in solution), Ras-
GRF2 (500 ng), 10 mM GTP and 2.3 µCi [α-32P]GTP. After 0 or
30 min at 23°C, reactions were terminated by the addition of 2 ml ice-
cold stop buffer (25 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2),
and filtration over 0.45 micron pore-size nitrocellulose followed by three
washes with stop buffer. Dried filters were dissolved in ethyleneglycol
monomethylether and quantified by liquid scintillation counting. Values
are ± s.e.m. and corrected by subtraction of spontaneous nucleotide
exchange which occurred during the 30 min incubation period.
MAPK assays
Cells (293T) were transiently co-transfected with 3 µg pJ3M-ERK1 (for
ERK1 assays) [6], and 3 µg of either pcDNA3 plasmid (vector) or ver-
sions encoding Ras-GRF2 (WT) or the mutants derivatives ∆IQ, ∆DH,
∆Cdc25, as indicated in the figures in the main paper. After 48 h, cells
were serum starved for 18 h, and then stimulated with 1–5 µM iono-
mycin for 5 min at 37°C, washed in ice-cold phosphate-buffered saline
(PBS), then lysed in TX lysis buffer (20 mM Tris-HCl pH 7.5, 1 mM
MgCl2, 150 mM NaCl, 1% Triton X-100, 50 mM NaF, 200 µM Na-ortho-
vanadate, 40 mM sodium pyrophosphate, 40 mM β-glycerophosphate,
10 µg aprotinin/ml, 0.1 mM AEBSF). Phosphorylation of MBP by
immunoprecipitated ERK1 was determined as previously described [4].
For SAPK assays, 293T cells were co-transfected with 3 µg pMT2-
HA–SAPKβ, and 3 µg of either pcDNA3 or pcDNA3-FLAG–GRF2;
48 h post-transfection, cells were deprived of serum for 18 h and then
treated with either ionomycin (as described above) or 2 µg/ml ani-
somycin (Sigma) for 5 or 10 min, respectively. Lysates were prepared as
described above, and 20 µg cellular protein was resolved on a 15%
polyacrylamide gel containing SDS. Immunoblot analysis was performed
by using a phospho-specific polyclonal antibody to SAPK (New England
Biolabs), secondary goat anti-rabbit antibodies conjugated to horserad-
ish peroxidase, and enhanced chemiluminescence imaging (Pierce).
SAPK activity was analyzed as described [S4]. GST–c-Jun phosphory-
lation was visualized by autoradiography and quantified with a Bio-Rad
GS-250 phosphorimager. For experiments depicted in Figure 4 of the
paper, the DNA transfections included 2 µg pcDNA3-Ras-N17 or
pRK5-Myc–Rac1-N17 as indicated.
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